[Results of a multicenter trial of serenoa repens extract (permixon) in patients with chronic abacterial prostatitis].
Chronic prostatitis (CP) morbidity now makes up 8 to 35% in males aged 20-40 years (N.A. Lopatkin et al., 1998; O.L. Tiktinsky, 1999). In general population CP incidence rate is 5 to 8% (J.C. Nickel, 1999). Phytotherapy is now widely practiced in CP. A multicenter trial conducted by the authors demonstrates high efficacy ofpermixon in the treatment of chronic prostatitis/chronic pelvic pain syndrome. The results of 6-month follow-up are presented.
Lopatkin
N A
NA
Apolikhin
O I
OI
Sivkov
A V
AV
Aliaev
Iu G
IuG
Komiakov
B K
BK
Zhuravlev
V N
VN
Oshchepkov
V N
VN
Vinarov
A Z
AZ
Bazhenov
I V
IV
Medvedev
A A
AA
Spivak
L G
LG
Eliseenko
A G
AG
D000293:Adolescent; D000328:Adult; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010936:Plant Extracts / Q000009:adverse effects / Q000627:therapeutic use*; D011472:Prostatitis / Q000188:drug therapy*; D028024:Serenoa; D016896:Treatment Outcome
D000726:Androgen Antagonists; D010936:Plant Extracts; C040972:saw palmetto extract